Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of second-course maintenance olaparib after recurrence in platinum-sensitive BRCA-mutated high-grade serous ovarian cancer
2015-003883-36Phase 2Unknown
- Sponsor
- The Christie
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and cediranib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by The Christie. Primary endpoint: Proportion remaining on second-course olaparib for at least 6 months. Status: unknown.
02
Drugs
olaparibcediranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2015-003883-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003883-36.